CPH Group (CPHN) investor relations material

Executive summary

• Sales remained stable at CHF 176.1 million in H1 2026, with EBITDA at CHF 28.3 million (down 6.3% year-over-year, up 41% from H2 2025), and an EBITDA margin of 16.1% (up from 15.0% in FY 2025).

• Net result was CHF 14.3 million, down 16.4% year-over-year but more than double H2 2025; free cash flow improved to CHF 12.8 million from negative CHF 1.8 million in H1 2025.

• Transformation into two divisions advanced, integrating Sorbchem, LOG Pharma, and SiliCycle, establishing a solid basis for growth and stable cash flows.

• Board approved a higher dividend payout ratio, targeting 40–60% of net result.

Financial highlights

• Group sales for H1 2026 were CHF 176.1 million, flat year-over-year; EBITDA CHF 28.3 million (down 6.3%), EBIT CHF 19.0 million (down 13.4%), and net result CHF 14.3 million (down 16.4%).

• Gross profit increased by 2.1% to CHF 86.3 million, with a margin of 49.0%.

• Free cash flow improved to CHF 12.8 million from negative CHF 1.8 million in H1 2025.

• Equity ratio at 54% as of June 30, 2026.

Outlook and guidance

• Full-year 2026 sales and EBITDA expected slightly higher than 2025; EBIT and net result to remain broadly in line with prior year, assuming stable FX and no major geopolitical escalation.

• Perlen Packaging anticipates higher sales and EBITDA; Zeochem expects higher sales but slightly lower EBITDA.

• Mid-term targets confirmed: sales growth 5–8% p.a., EBITDA margin 16–18%, free cash flow margin 8–10%, payout ratio raised to 40–60%.